Patents Assigned to Hybrigenics S.A.
  • Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
    Patent number: 10478497
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 19, 2019
    Assignee: HYBRIGENICS S.A.
    Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne
  • Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof
    Patent number: 6916615
    Abstract: The present invention concerns collections of recombinant cell clones derived from a prokaryotic genome, more particularly from Helicobacter pylori genome, useable for two-hybrid systems and methods to produce such collections. The invention further relates to then identification of H. pylori protein-protein interactions and to the application of said collections of recombinant cell clones and said identified proteins interactions to the pharmaceutical and diagnostic field.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: July 12, 2005
    Assignee: Hybrigenics S.A.
    Inventors: Pierre Legrain, Luc Selig, Jean-Christophe Rain